Full Text
EPH29 The Cost of Managing Safety Events: Ozanimod Versus Tofacitinib – A UK Perspective

Abstract

Authors

J Paris S Stephens L Oddershede K Davé

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×